OrbusNeich announced the publication of a study demonstrating that lesion preparation with the company’s Scoreflex coronary dilatation catheter prior to drug eluting stent (DES) implantation is associated with equivalent acute stent expansion and less in-stent late loss versus a non-compliant balloon.

Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy and safety of the Orsiro Hybrid Drug-Eluting Stent (DES) from Biotronik.

Alivecor Inc. announced that the AliveCor Heart Monitor is now being offered to participants in the Health eHeart Study with 2,000 units to be deployed before the end of the year.

Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.

CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal denervation devices.

The global sales of drug-eluting balloons (DEBs) across the 10 major markets (10MM) are expected to witness a significant increase over the coming years, from $164m in 2012 to $477m in 2019, at a Compound Annual Growth Rate (CAGR) of 16 percent, following the product’s launch in the United States and Japanese markets, according to a new report from research and consulting firm GlobalData.

Kona Medical Inc. announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is the sole investor.